THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL No. 2378 Session of 1996

INTRODUCED BY BROWNE, NAILOR, BELARDI, HERMAN, EGOLF, M. N. WRIGHT, PISTELLA, TIGUE, L. I. COHEN, GEIST, DENT, MELIO, SCHRODER, E. Z. TAYLOR, YOUNGBLOOD, TULLI, J. TAYLOR AND TRELLO, FEBRUARY 6, 1996

REFERRED TO COMMITTEE ON FINANCE, FEBRUARY 6, 1996

AN ACT

1 2 3 4 5 6 7 8 9 10 11	Amending the act of March 4, 1971 (P.L.6, No.2), entitled "An act relating to tax reform and State taxation by codifying and enumerating certain subjects of taxation and imposing taxes thereon; providing procedures for the payment, collection, administration and enforcement thereof; providing for tax credits in certain cases; conferring powers and imposing duties upon the Department of Revenue, certain employers, fiduciaries, individuals, persons, corporations and other entities; prescribing crimes, offenses and penalties," providing for a research and orphan drug tax credit.
12	The General Assembly of the Commonwealth of Pennsylvania
13	hereby enacts as follows:
14	Section 1. The act of March 4, 1971 (P.L.6, No.2), known as
15	the Tax Reform Code of 1971, is amended by adding an article to
16	read:
17	ARTICLE XVII-B
18	RESEARCH TAX AND ORPHAN DRUG CREDITS
19	Section 1701-B. Short TitleThis article shall be known
20	and may be cited as the Pennsylvania Research Tax and Orphan
21	Drug Credit Law.

1	Section 1702-B. DefinitionsThe following words and
2	phrases, when used in this article shall have the meanings
3	ascribed to them in this section, except where the context
4	<u>clearly indicates a different meaning:</u>
5	"Base period." The three consecutive taxable-year period
6	ending with the taxable year immediately preceding the last
7	taxable year beginning after December 31, 1994.
8	"Basic research." Any original investigation for the
9	advancement of scientific knowledge not having a specific
10	commercial objective.
11	"Clinical testing." Any human clinical testing which meets
12	all of the following criteria:
13	(1) Testing which is carried out under an exemption for a
14	drug being tested for a rare disease or condition under section
15	505(I) of the Federal Food, Drug, and Cosmetic Act(52 Stat.
16	1040, 21 U.S.C. § 301 et seq.) or any regulations promulgated
17	thereunder.
18	(2) Testing which occurs:
19	(i) after the date such drug is designated under section 526
20	of the Federal Food, Drug, and Cosmetic Act (52 Stat. 1040, 21
21	<u>U.S.C. § 301 et seq.);</u>
22	(ii) before the date on which an application with respect to
23	such drug is approved under section 505(b) or 507 of the Federal
24	Food, Drug, and Cosmetic Act (52 Stat. 1040, 21 U.S.C. § 301 et
25	seq.) or, if the drug is a biological product, before the date
26	on which a license for that drug is issued under section 351 of
27	the Public Health Service Act (58 Stat. 682, 42 U.S.C. § 201 et
28	seq.); and
29	(iii) which is conducted by or on behalf of the taxpayer to
30	whom the designation under section 526 of the Federal Food,
100	60u2278p2081 _ 2 _

- 2 -

1 Drug, and Cosmetic Act (52 Stat. 1040, 21 U.S.C. § 301 et seq.)
2 applies.

3	"Contract clinical testing expenses." One hundred per cent
4	of any amount paid or incurred by the taxpayer to any person,
5	other than an employe of the taxpayer, for qualified clinical
6	testing. If any contract clinical testing expenses paid or
7	incurred during any taxable year are attributable to qualified
8	clinical testing conducted after the close of the taxable year,
9	the amount so determined shall be treated as paid or incurred
10	during the tax year in which the qualified clinical testing is
11	conducted.
12	"Contract research expenses." Sixty-five per cent of any
13	amount paid or incurred by the taxpayer to any person, other
14	than an employe of the taxpayer, for qualified research. If any
15	contract research expenses paid or incurred during any taxable
16	year are attributable to qualified research conducted after the
17	close of the taxable year, the amount so determined shall be
18	treated as paid or incurred during the tax year in which the
19	qualified research is conducted.
20	"Credit." The research tax credit made available under the
21	provisions of this article.
22	"In-house clinical testing expenses." Any one of the
23	<u>following:</u>
24	(1) Any wages paid or incurred to any employe for qualified
25	services performed by that employe.
26	(2) Any amount paid or incurred for supplies used in the
27	conduct of qualified clinical testing.
28	(3) Subject to regulations of the department, any amount
29	paid or incurred to another person for the right to use
30	computers in the conduct of qualified clinical testing, except
199	60H2378B3081 - 3 -

1	that this clause shall not apply to any amount to the extent
2	that the taxpayer receives or accrues any amount from any other
3	person for the right to use substantially identical personal
4	property.
5	"In-house research expenses." Any one of the following:
6	(1) Any wages paid or incurred to any employe for qualified
7	services performed by that employe.
8	(2) Any amount paid or incurred for supplies used in the
9	conduct of qualified research.
10	(3) Subject to regulations of the department, any amount
11	paid or incurred to another person for the right to use
12	computers in the conduct of qualified research, except that this
13	clause shall not apply to any amount to the extent that the
14	taxpayer receives or accrues any amount from any other person
15	for the right to use substantially identical personal property.
16	"Internal Revenue Code." The Internal Revenue Code of 1986
17	<u>(Public Law 99-514, 26 U.S.C. § 1 et seq.).</u>
18	"Qualified clinical testing expenses." The sum of the in-
19	house clinical testing expenses and the contract clinical
20	testing expenses which are paid or incurred by the taxpayer
21	during the taxable year for which the orphan drug credit is
22	claimed.
23	"Qualified research expenses." The sum of the in-house
24	research expenses and the contract research expenses which are
25	paid or incurred by the taxpayer during the taxable year for
26	which the research credit is claimed.
27	"Qualified services." Services consisting of engaging in
28	qualified research, or engaging in the direct supervision or
29	direct support of research activities which constitute qualified
30	research.

- 4 -

1	"Supplies." Any tangible property, other land or improvement
2	to land and any property of a character subject to depreciation.
3	"Wages." Compensation as defined in section 301.
4	<u>Section 1703-B. Research Tax Credit(a) Any taxpayer</u>
5	subject to Articles IV, VI or XI shall be eligible for and may
6	claim a research tax credit or orphan drug credit as provided in
7	this article.
8	(b) (1) Subject to the overall limitation set forth in
9	clause (2), the amount of the research tax credit under this
10	article for any taxable year shall be equal to the sum of:
11	(i) five per cent of the excess, if any, of the qualified
12	research expenses for the taxable over the base amount; plus
13	(ii) five per cent of the basic research payments determined
14	under section 1707-B; plus
15	(iii) five per cent of the applicable percentage of qualified
16	research and development property; plus
17	(iv) ten per cent of the applicable percentage of qualified
18	wages paid to jobs created in research and development
19	activities.
20	(2) The amount of the research tax credit under this article
21	for any taxable year shall not exceed fifty per cent of the tax
22	liability for that taxpayer in that tax year.
23	(3) The amount of any research tax credit otherwise
24	allowable which cannot be taken because of the limitation under
25	clause (2) may be carried forward to the next three succeeding
26	tax years.
27	<u>Section 1704-B. Orphan Drug Credit(a) There shall be</u>
28	allowed as a credit against tax imposed by Article IV, VI or IX
29	for the taxable year an amount equal to 50 per cent of the
30	qualified clinical testing expenses for the taxable year.
199	60H2378B3081 - 5 -

- 5 -

1	(b) The term "qualified clinical testing expenses" shall not
2	include any amount to the extent such amount is funded by any
3	grant, contract or otherwise by another person or any other
4	governmental entity.
5	(c) Human clinical testing shall be taken into account under
6	subsection (a) only to the extent such testing is related to the
7	use of a drug for the rare disease or conditions for which it
8	was designated under section 526 of the Federal Food, Drug, and
9	<u>Cosmetic Act (52 Stat. 1040, 21 U.S.C. § 301 et seq.).</u>
10	(d) For purposes of this section, the term "rare disease or
11	condition means any disease or condition which:
12	(1) affects less than 200,000 persons in the United States;
13	or
14	(2) affects more than 200,000 persons in the United States
15	but which there is no reasonable expectation that the cost of
16	developing and making available a drug for such disease or
17	condition will be recovered from the worldwide sales of such a
18	<u>drug.</u>
19	Determinations under the preceding sentence with respect to any
20	drug shall be made on the basis of the facts and circumstances
21	as of the date such drug is designated under section 526 of the
22	Federal Food, Drug, and Cosmetic Act.
23	(e) No credit shall be allowed under this section with
24	respect to any clinical testing conducted outside this
25	Commonwealth.
26	(f) This section shall apply to any taxpayer for any taxable
27	year only if such taxpayer elects to have this section apply for
28	such taxable year in place of either section 1703-B(b)(1)(i) or
29	<u>section 1703-B(b)(1)(ii).</u>
30	<u>Section 1705-B. Base Amount(a) (1) The base amount is</u>

- 6 -

1	equivalent to the product of the fixed-base percentage and the
2	average annual gross receipts of the taxpayer for the four
3	consecutive taxable years immediately preceding the tax year for
4	which the research tax credit is claimed.
5	(2) In no event shall the base amount less than fifty per
6	cent of the qualified research expenses for the taxable year for
7	which the credit is claimed.
8	(b) (1) Except as otherwise provided in this subsection,
9	the fixed-base percentage is the percentage which the aggregate
10	research expenses of the taxpayer for the four consecutive
11	taxable years immediately preceding the tax year for which the
12	credit is claimed is to the aggregate gross receipts of the
13	taxpayer for such four consecutive taxable years.
14	(2) The fixed-base percentage for a taxpayer who has less
15	than four consecutive taxable years shall be determined in the
16	same manner as set forth in clause (1) using the number of
17	immediately preceding taxable years to arrive at the percentage.
18	(3) In no event shall the fixed-base percentage exceed
19	<u>sixteen per cent.</u>
20	(c) For purposes of this section, gross receipts for any
21	taxable year shall:
22	(i) be reduced by returns and allowances made during the
23	taxable year; and
24	(ii) shall only consist of gross receipts which are
25	effectively connected with the conduct of a trade or business
26	within this Commonwealth.
27	<u>Section 1706-B. Qualified Research(a) Qualified research</u>
28	is research which complies with all of the following criteria:
29	(1) Expenditures on the research may be treated as expenses
30	under section 175 of the Internal Revenue Code.
100	COTT022001 7

- 7 -

1	(2) Research is undertaken for the purpose of discovering
2	information which is technological in nature and the application
3	of which information is intended to be useful in the development
4	of a new or improved business component for the taxpayer.
5	(3) Substantially all of the activities constitute elements
6	of a process of experimentation for a purpose described in
7	subsection (b) of this section.
8	(b) (1) Research may qualify for a credit under this
9	article if that research relates to any of the following:
10	(i) A new or improved function.
11	<u>(ii) Performance.</u>
12	<u>(iii) Reliability or quality.</u>
13	(2) A tax credit under this article shall not be allowed for
14	any of the following types of research:
15	(i) Any research conducted after the beginning of commercial
16	production of the business component.
17	(ii) Any research related to the adaptation of an existing
18	business component to a particular customer's need.
19	(iii) Any research related to the reproduction of an
20	existing business component from a physical examination of the
21	business component itself or from plans, blueprints, detailed
22	specifications or publicly available information with respect to
23	the business component.
24	(iv) Any efficiency survey; activity related to management
25	function or technique; market research, testing or development;
26	routine data collection; or routine or ordinary testing or
27	inspection for quality control.
28	(v) Any research with respect to computer software which is
29	developed by or for the benefit of the taxpayer, other than
30	computer software for use in an activity which constitutes
199	60H2378B3081 - 8 -

1 qualified research, or a production process which meets the requirements of subsection (a) of this section. 2 3 (vi) Any research conducted outside the Commonwealth. If the 4 taxpayer has research within and without Pennsylvania and cannot 5 determine the amount of Pennsylvania qualified research expenses for the period beginning after December 31, 1991, and before 6 January 1, 1995, the amount to be used in the numerator for the 7 8 fixed based percentage should be gualified research and 9 development expenditures everywhere for the period multiplied by 10 the average of the payroll and property factors used on the 11 corporation's Corporate Tax Report for the Corporate Net Income Tax imposed under Article IV of this act for the corresponding 12 13 years in question. 14 (vii) Any research in the social sciences, arts or the 15 humanities. 16 (viii) Any research to the extent funded by a grant, 17 contract or otherwise by another person or governmental entity. 18 Section 1707-B. Basic Research Payments.--(a) For purposes of section 1703-B of this article, the amount of any basic 19 20 research payments shall be equal to the excess of such basic 21 research payments over the qualified organization base period 22 amount. The portion of the basic research payment which does not 23 exceed the qualified organization base period amount shall be 24 treated as contract research expenses. 25 (b) As used in this section, the term "basic research 26 payment" means any amount paid in cash during the tax year for 27 which credit is claimed by the taxpayer to a qualified 28 organization for basic research if such payment is made under 29 written agreement between that taxpayer and the qualified organization and the basic research is to be performed by that 30 19960H2378B3081

- 9 -

1 <u>qualified organization.</u>

-	
2	(c) (1) The qualified organization base period amount is an
3	amount equal to the sum of the minimum basic research amount
4	plus the maintenance-of-effort amount.
5	(2) Minimum basic research amount is an amount equal to the
б	greater of:
7	(i) one per cent of the average of the sum of amount paid or
8	incurred during the base period for in-house research expenses
9	and any contract research expenses; or
10	(ii) the amounts treated as contract expenses during the
11	base period by reason of subsection (a) of this section. The
12	minimum basic research amount for any base period shall not be
13	less than fifty per cent of the basic research payments for the
14	tax year for which credit is claimed.
15	(3) Maintenance-of-effort amount is an amount equal to the
16	excess, if any, of an amount equal to the average of the
17	nondesignated higher education contributions paid by the
18	taxpayer during the base period multiplied by the cost-of-living
19	adjustment for the calendar year in which the tax year begins
20	over the amount of nondesignated higher education contributions
21	paid by the taxpayer during the tax year for which credit is
22	<u>claimed.</u>
23	(4) Nondesignated higher education contribution is any
24	amount paid by a taxpayer to a qualified institution of higher
25	education for which a deduction is allowable under section 170
26	of the Internal Revenue Code and which amount was not used to
27	<u>compute a credit under this article or as a basic research</u>
28	payment for purposes of this article.
29	(5) Cost-of-living adjustment for any calendar year is the
30	cost-of-living adjustment for such calendar year calculated
199	60H2378B3081 - 10 -

1	under section 1(f)(3) of the Internal Revenue Code.
2	Section 1708-B. Qualified research and development
3	property(a) The cost of land and depreciable property
4	purchased for the conduct of research and development which is
5	placed in service or used in this Commonwealth during the
6	taxable year shall be the base from which the qualified research
7	and development property factor is calculated.
8	(b) (1) For the purpose of subsection (a), the applicable
9	percentage for land and depreciable property shall be determined
10	under the following table:
11	If useful life is: <u>The applicable percentage is:</u>
12	Less than 6 years 33 1/3%
13	<u>6 years or more but</u>
14	less than 8 years <u>66 2/3%</u>
15	<u>8 years or more</u> 100%
16	(2) The useful life of any property for purposes of this
17	section shall be determined as of the date such property is
18	first placed in service or use in this Commonwealth by the
19	taxpayer.
20	(c) For purposes of subsection (a), the cost of each
21	property purchased for the conduct of research and development
22	shall be determined under the following rules:
23	(1) Cost shall not include the value of property given in
24	trade or exchange for the property purchased for the conduct of
25	research and development.
26	(2) For property damaged or destroyed by fire, flood, storm
27	or other casualty, or stolen, the cost of replacement property
28	shall not include any insurance proceeds received in
29	compensation for the loss.
30	(3) The cost of property acquired by lease for a term of ten

- 11 -

years or longer shall be one hundred per cent of the rent 1 2 reserved for the primary term of the lease, not to exceed twenty 3 years. 4 (4) The cost of property purchased for multiple business use 5 including direct use in the conduct of research and development, together with some other business or activity not eligible under 6 this section, shall be apportioned between such activities. The 7 8 amount apportioned to the conduct of research and development 9 shall be considered to be eligible investment subject to the 10 conditions and limitations of this section. 11 (5) In the case of self-constructed property, the cost 12 thereof shall be the amount properly charged to the capital 13 account for depreciation in accordance with the provisions of 14 the Internal Revenue Code. 15 Section 1709-B. Applicable Percentage of Qualified Research 16 and Development Wages.--(a) (1) For purposes of section 1703-17 B, the applicable percentage of qualified research and 18 development wages for the taxable year shall be equal to the 19 following: 20 (i) Forty per cent of the qualified first year wages for 21 such year. 22 (ii) Twenty per cent of the qualified second year wages for 23 such year. 24 (iii) Twenty per cent of the qualified third year wages for 25 such year. 26 (iv) Twenty per cent of the qualified fourth year wages for 27 such year. 28 (2) (i) The amount of qualified first, second, third or 29 fourth year wages, which may be taken into account with respect 30 to any individual, shall be the amount of wages which exceed the

19960H2378B3081

- 12 -

1	base amount wages of ten thousand dollars (\$10,000).
2	(ii) The base amount wages will be adjusted on an annual
3	basis by the Secretary of Revenue to account for any increase or
4	decrease in the consumer price index (CPI) in the previous
5	<u>calendar year.</u>
б	(b) As used in this section, the following words and phrases
7	shall have the meanings given to them in this subsection:
8	"Qualified wages." The wages paid or incurred by the
9	employer during the taxable year to individuals who are employed
10	in research development activities.
11	"Yearly wages." The qualified wages attributable to service
12	rendered during a yearly period beginning with the day the
13	individual begins work with the employer.
14	Section 2. This act shall take effect January 1, 1997.